Multidrug-resistant Gram-negative bacteria: how to treat and for how long (Q37815675)

23 August 2017

1 reference

title

Multidrug-resistant Gram-negative bacteria: how to treat and for how long (English)

1 reference

bacterial multiple drug resistance

23 August 2017

main subject

gram-negative bacteria

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21129924

19 November 2024

0 references

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21129924

19 November 2024

publication date

3 December 2010

1 reference

full work available at URL

23 August 2017

https://hal.archives-ouvertes.fr/hal-00650375/file/PEER_stage2_10.1016%252Fj.ijantimicag.2010.11.014.pdf

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21129924

https://api.elsevier.com/content/article/PII:S0924857910004759?httpAccept=text/xml

19 November 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

https://api.elsevier.com/content/article/PII:S0924857910004759?httpAccept=text/plain

19 November 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

International Journal of Antimicrobial Agents

19 November 2024

published in

1 reference

23 August 2017

volume

36 Suppl 2

1 reference

23 August 2017

page(s)

S50-4

1 reference

Multidrug-resistant Gram-negative infections: what are the treatment options?

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Old polymyxins are back: is resistance close?

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa.

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Treatment options for multidrug-resistant bacteria.

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Ventilator-associated pneumonia due to colistin susceptible-only microorganisms

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Inhaled anti-infective agents: emphasis on colistin

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Post-neurosurgical multidrug-resistant Acinetobacter baumannii meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the Asia-Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST).

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Tigecycline pharmacokinetic/pharmacodynamic update

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control.

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial

19 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.IJANTIMICAG.2010.11.014

19 November 2024

Identifiers

DOI

1 reference

23 August 2017

1 reference